317 related articles for article (PubMed ID: 21401573)
1. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
[TBL] [Abstract][Full Text] [Related]
2. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
3. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
[TBL] [Abstract][Full Text] [Related]
4. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
Pich A; Riera L; Sismondi F; Godio L; Davico Bonino L; Marmont F; Francia di Celle P
J Clin Pathol; 2009 Sep; 62(9):798-801. PubMed ID: 19734476
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
Patnaik MM; Parikh SA; Hanson CA; Tefferi A
Br J Haematol; 2014 May; 165(3):273-86. PubMed ID: 24467717
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelomonocytic leukemia: myeloproliferative variant.
Onida F; Beran M
Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
[TBL] [Abstract][Full Text] [Related]
7. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
8. Current status of allogeneic HST for chronic myelomonocytic leukemia.
Cheng H; Kirtani VG; Gergis U
Bone Marrow Transplant; 2012 Apr; 47(4):535-41. PubMed ID: 21743499
[TBL] [Abstract][Full Text] [Related]
9. CMML: a biologically distinct myeloproliferative disease.
Cortes J
Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
[TBL] [Abstract][Full Text] [Related]
10. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
Elliott MA; Tefferi A; Hogan WJ; Letendre L; Gastineau DA; Ansell SM; Dispenzieri A; Gertz MA; Hayman SR; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Litzow MR
Bone Marrow Transplant; 2006 Jun; 37(11):1003-8. PubMed ID: 16604096
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience.
Krishnamurthy P; Lim ZY; Nagi W; Kenyon M; Mijovic A; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Oct; 45(10):1502-7. PubMed ID: 20098454
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
14. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.
Elliott MA
Best Pract Res Clin Haematol; 2006; 19(3):571-93. PubMed ID: 16781489
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myelomonocytic leukemia: from diagnosis to treatment].
Hafraoui K; De Prijck B; Beguin Y
Rev Med Suisse; 2013 Aug; 9(395):1512, 1514-7. PubMed ID: 24024420
[TBL] [Abstract][Full Text] [Related]
17. Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.
Coltro G; Patnaik MM
Curr Oncol Rep; 2019 Nov; 21(11):101. PubMed ID: 31728739
[TBL] [Abstract][Full Text] [Related]
18. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
Patnaik MM; Tefferi A
Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia.
Ngo NT; Lampert IA; Naresh KN
Br J Haematol; 2008 Jun; 141(6):771-81. PubMed ID: 18371110
[TBL] [Abstract][Full Text] [Related]
20. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]